U.S. markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9400-0.0900 (-4.43%)
At close: 4:00PM EDT
1.9500 +0.01 (+0.52%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close2.0300
Bid1.9400 x 2200
Ask1.9500 x 36900
Day's Range1.8600 - 2.0000
52 Week Range0.8730 - 4.5600
Avg. Volume2,648,387
Market Cap283.199M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.2790
Earnings DateDec 14, 2021 - Dec 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CTXR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Citius Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.
    Fair Value
    Economic Moat
    last yearMorningstar
View more
  • PR Newswire

    Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m. ET to discuss the Company's previously announced acquisition of I/ONTAK (E7777), an improved formulation of immunotoxin ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

  • PR Newswire

    Citius Pharmaceuticals to Present at Upcoming October Investor Conferences

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.

  • Insider Monkey

    10 Reddit’s WallStreetBets Stocks Under $5

    In this article, we discuss the 10 Reddit’s WallStreetBets stocks under $5. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit’s WallStreetBets Stocks Under $5. Reddit forum WallStreetBets, with a user base of close to 11 million, is one of the hottest places in the finance world, […]